EA200201252A1 - Соединения, эффективные в качестве агонистов э2 - адренорецептора и ингибиторов фосфодиэстеразы pde4 - Google Patents

Соединения, эффективные в качестве агонистов э2 - адренорецептора и ингибиторов фосфодиэстеразы pde4

Info

Publication number
EA200201252A1
EA200201252A1 EA200201252A EA200201252A EA200201252A1 EA 200201252 A1 EA200201252 A1 EA 200201252A1 EA 200201252 A EA200201252 A EA 200201252A EA 200201252 A EA200201252 A EA 200201252A EA 200201252 A1 EA200201252 A1 EA 200201252A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phosphodiesterrase
adrenoreceptor
pde4
agonists
inhibitors
Prior art date
Application number
EA200201252A
Other languages
English (en)
Other versions
EA005824B1 (ru
Inventor
Ивонне Ван-Дер-Лан
Хендрик Тиммерманн
Йоханнес Кристианс
Паулус Брундель
Герт Стерк
Original Assignee
Алтана Фарма Аг
Алтана Фарма Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алтана Фарма Аг, Алтана Фарма Б.В. filed Critical Алтана Фарма Аг
Publication of EA200201252A1 publication Critical patent/EA200201252A1/ru
Publication of EA005824B1 publication Critical patent/EA005824B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описаны соединения формулы I, где Ar, A, R6, R7, R8 и Arимеют значения, указанные в описании заявки, которые являются новыми эффективными бронхиальными лекарственными средствами.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200201252A 2000-06-05 2001-06-01 СОЕДИНЕНИЯ, ЭФФЕКТИВНЫЕ В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРА И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ PDE4 EA005824B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00111795 2000-06-05
PCT/EP2001/006230 WO2001094319A1 (en) 2000-06-05 2001-06-01 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors

Publications (2)

Publication Number Publication Date
EA200201252A1 true EA200201252A1 (ru) 2003-06-26
EA005824B1 EA005824B1 (ru) 2005-06-30

Family

ID=8168897

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201252A EA005824B1 (ru) 2000-06-05 2001-06-01 СОЕДИНЕНИЯ, ЭФФЕКТИВНЫЕ В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРА И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ PDE4

Country Status (20)

Country Link
US (1) US6933296B2 (ru)
EP (1) EP1296956A1 (ru)
JP (1) JP2003535850A (ru)
KR (1) KR20030031907A (ru)
CN (1) CN1471515A (ru)
AU (2) AU6233201A (ru)
BR (1) BR0111440A (ru)
CA (1) CA2411351A1 (ru)
CZ (1) CZ20023997A3 (ru)
EA (1) EA005824B1 (ru)
HK (1) HK1052346A1 (ru)
HU (1) HUP0301240A3 (ru)
IL (1) IL152846A0 (ru)
MX (1) MXPA02012042A (ru)
NO (1) NO20025811L (ru)
NZ (1) NZ522882A (ru)
PL (1) PL358057A1 (ru)
SK (1) SK17052002A3 (ru)
WO (1) WO2001094319A1 (ru)
ZA (1) ZA200209598B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05386B1 (et) 2001-02-15 2011-02-15 ALTANA�Pharma�AG Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim
EP1385838A1 (en) 2001-04-25 2004-02-04 ALTANA Pharma AG Piperazino-derivatives and their use as pde4 inhibitor
CA2445233A1 (en) 2001-04-25 2002-10-31 Altana Pharma Ag Phthalazinones derivatives useful as pde4/7 inhibitors
ES2195785B1 (es) * 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US20060167001A1 (en) * 2002-08-10 2006-07-27 Sterk Jan G Pyridazinone-derivatives as pde4 inhibitors
WO2004018457A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
WO2004018450A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-n-oxide-derivatives
JP2006513222A (ja) * 2002-12-23 2006-04-20 アルテシアン セラピューティック，インコーポレイティド アドレナリン性β受容体およびホスホジエステラーゼに対する抑制活性を有する強心性化合物
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1716123A1 (en) * 2004-02-04 2006-11-02 Altana Pharma AG Pyridazinone derivatives and their use as pde4 inhibitors
JP4778449B2 (ja) * 2004-02-04 2011-09-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしての２−（ピペリジン−４−イル）−４，５−ジヒドロ−２ｈ−ピリダジン−３−オン誘導体
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
GB0805535D0 (en) 2008-03-27 2008-04-30 Univ Leicester Scar prevention
EP2323991B1 (en) * 2008-08-13 2017-05-31 Boehringer Ingelheim International GmbH Chymase inhibitors
CA2796826A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
BR112013031791A2 (pt) * 2011-06-17 2017-01-31 Takeda Gmbh derivados de ftalazinona-pirrolopirimidinacarboxamida
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
GB2513297A (en) 2013-03-08 2014-10-29 Univ Leicester Methods
JP2022506686A (ja) 2018-11-06 2022-01-17 エッジワイズ セラピューティクス， インコーポレイテッド ピリダジノン化合物およびその使用
EA202191084A1 (ru) 2018-11-06 2021-10-19 Эджвайз Терапьютикс, Инк. Соединения пиридазинонов и их применения
WO2021231572A1 (en) * 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3063196D1 (en) * 1979-12-05 1983-06-16 Morishita Pharma Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
JPS58146571A (ja) * 1982-02-25 1983-09-01 Morishita Seiyaku Kk ウレア誘導体およびその製造法
PL164079B1 (pl) * 1990-06-15 1994-06-30 Akad Medyczna posób wytwarzania nowych 2-amlnoalkilopochodnych 5-aminometyleno-6-/p-chlorofenylo /-4,5-dihydro-2H- plrydazyn -3-onu
DE69332762T2 (de) 1992-12-02 2003-08-14 Pfizer Inc., New York Cathecoldiether als selektive pde iv hemmungsmittel
DE19533975A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
ATE233247T1 (de) 1997-01-15 2003-03-15 Altana Pharma Ag Phtalazinonen
PT975347E (pt) 1997-02-28 2008-05-23 Nycomed Gmbh Combinação sinérgica de inibidores da pde e agonistas da adenilato ciclase ou agonistas da guanil ciclise
AU1760399A (en) 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
AU753576B2 (en) 1997-12-15 2002-10-24 Altana Pharma Ag Dihydrobenzofurans
EP0934933A1 (en) 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
EP1107747A4 (en) 1998-08-26 2003-04-23 Smithkline Beecham Corp COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES

Also Published As

Publication number Publication date
NO20025811D0 (no) 2002-12-03
AU6233201A (en) 2001-12-17
HUP0301240A2 (hu) 2003-12-29
KR20030031907A (ko) 2003-04-23
EP1296956A1 (en) 2003-04-02
SK17052002A3 (sk) 2003-12-02
AU2001262332B2 (en) 2006-05-25
MXPA02012042A (es) 2004-08-19
IL152846A0 (en) 2003-06-24
CN1471515A (zh) 2004-01-28
WO2001094319A1 (en) 2001-12-13
US6933296B2 (en) 2005-08-23
CA2411351A1 (en) 2001-12-13
EA005824B1 (ru) 2005-06-30
HUP0301240A3 (en) 2004-03-29
CZ20023997A3 (cs) 2003-05-14
NZ522882A (en) 2004-07-30
PL358057A1 (en) 2004-08-09
JP2003535850A (ja) 2003-12-02
NO20025811L (no) 2003-02-04
US20030195215A1 (en) 2003-10-16
BR0111440A (pt) 2003-06-03
ZA200209598B (en) 2003-07-29
HK1052346A1 (zh) 2003-09-11

Similar Documents

Publication Publication Date Title
EA200201252A1 (ru) Соединения, эффективные в качестве агонистов э2 - адренорецептора и ингибиторов фосфодиэстеразы pde4
EA200100688A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
EA200400361A1 (ru) Производные алкинарилнафтиридин-4(1h)-онов в качестве ингибитора фосфодиэстеразы типа iv
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
EA200300836A1 (ru) Производные фталазинон-пиперидина в качестве ингибиторов pde4
EA200400284A1 (ru) Антинеопластические комбинации
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
EA200000768A1 (ru) ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
EA200101232A1 (ru) Соединения феноксипропиламина
BR0317715A (pt) Composições e processos de uso de collajolie
EA200500017A1 (ru) Новые соединения
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
EA200200381A1 (ru) Тетрагидротиопиранфталазиноновые производные в качестве ингибиторов pde4
EA200300450A1 (ru) Фармацевтические растворы соединений модафинила
EA200101017A1 (ru) Ингибиторы связывания lfa-1 с icam и их использование
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EA200500486A1 (ru) Новые фармацевтические составы модафинила
EA200200091A1 (ru) Содержащая амброксол пастилка
EA200000628A1 (ru) Ингибиторы металлопротеаз матрикса

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU